A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions

Healthy SubjectsDrug-drug InteractionPharmacokineticsQuizartinib

Interventions

DRUG

Dabigatran Etexilate Mesylate

Single oral 150 mg capsule dose

DRUG

Quizartinib

Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)

Trial Locations (1)

Worldwide Clinical Trials, San Antonio